A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Leal Therapeutics, Inc
- Study ID
- NCT07734493
- Phase
- PHASE1
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Not accepted
Interventions
- LTX-001 once daily — DRUGLTX-001 40 mg and 60 mg administered as oral suspension
- Placebo — DRUGOral suspension without LTX-001
- LTX-001 twice daily — DRUGLTX-001 30 mg and 60 mg administered as oral suspension
Study Details
The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute exacerbation). Additional questions it aims to answer are: * how does the amount of the study drug in the body change over time (pharmacokinetics) * how does the study drug affect the symptoms of schizophrenia * how do certain markers in the blood change after administration of LTX-001 (pharmacodynamics) Researchers will compare different dose levels of LTX-001 to an inactive product (placebo) to see what differences there are between the two treatments. After successfully screening for the study, participants will stay in a research unit for about five weeks and return one week later for a follow-up visit.
Key Dates
- First listed
- Jul 29, 2026
- Start date
- Aug 31, 2026
- Status verified
- Aug 2026
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 90 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: PlaceboPlacebo
- Experimental: LTX-001 once dailyLTX-001
- Experimental: LTX-001 twice dailyLTX-001
Primary Outcome Measure
Safety and Tolerability - Adverse Events [ Time Frame: Screening through Day 42 ]
Central Contacts
- Clinical Trials Information Medical Monitor267-503-4800
- Study Director Medical Monitor
Locations (10)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Pillar Clinical Research, LLC | Little Rock | Arkansas | 72204 | Leslie Smith Leslie Smith, MD (PRINCIPAL_INVESTIGATOR) |
| Collaborative Neuroscience Research, LLC | Los Alamitos | California | 90720 | Study Recruiter (714)-891-0971 David Walling, PhD (PRINCIPAL_INVESTIGATOR) |
| University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - DeLand Clinical Research Unit | DeLand | Florida | 32720 | Bruce Rankin Bruce Rankin, MD (PRINCIPAL_INVESTIGATOR) |
| Behavioral Clinical Research, Inc. | Hollywood | Florida | 33021 | Leandro Rueda Olga Lapeyra, MD (PRINCIPAL_INVESTIGATOR) |
| CenExel Hollywood FL | Hollywood | Florida | 33024 | Edwin A Gomez 954-990-7649 Edwin A Gomez, MD (PRINCIPAL_INVESTIGATOR) |
| Innovative Clinical Research, Inc. | Miami Lakes | Florida | 33016 | Leandro Rueda Rishi Kakar, MD (PRINCIPAL_INVESTIGATOR) |
| CenExel iResearch, LLC | Decatur | Georgia | 30030 | Michael Mahaffey Kimball Johnson, MD (PRINCIPAL_INVESTIGATOR) |
| CBH Health LLC., dba CenExel Gaithersburg MD | Gaithersburg | Maryland | 20877 | Elia Acevedo-Diaz 301-251-4702 Elia Acevedo-Diaz, MD (PRINCIPAL_INVESTIGATOR) |
| Hassman Research Institute, LLC | Marlton | New Jersey | 08053 | Elan Cohen, MD (PRINCIPAL_INVESTIGATOR) |
| Pillar Clinical Research, LLC | Richardson | Texas | 75080 | Scott Bartley Scott Bartley, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Little Rock, AR
Related Studies
- Database Registry for Neural Network Biomarkers in PsychosisRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With SchizophreniaPHASE3 · Recruiting · Gedeon Richter Plc. · Culver City, California
- Ocrelizumab for Psychosis by AutoimmunityPHASE1/PHASE2 · Recruiting · The Methodist Hospital Research Institute · Houston, Texas
- Imaging Synapses With [11C] UCB-J in the Human BrainPHASE1 · Recruiting · Davidzon, Guido, M.D. · Palo Alto, California